Venture capital firm Latterell Venture Partners added $4m to the $12m raised in April by HemaQuest Pharmaceuticals.
HemaQuest Pharmaceuticals, a US-based developer of drugs to treat blood disorders, has raised $4m in its series B round extension.
Venture capital firm Latterell Venture Partners added $4m to the $12m raised in April from VCs Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures, the corporate venturing division of drugs company Eli Lilly.
HemaQuest’s $20m series A round closed in November 2007 from De Novo, Forward Ventures and Lilly Ventures. Bryan Dunnivant from Lilly Ventures was the initial chairman of HemaQuest’s board after the A round.
